KAGOTSEL®

Active material: Kagocel
When ATH: J05AX
CCF: The antiviral and immunomodulatory drugs. Inducer of interferon synthesis
ICD-10 codes (testimony): A60, B00, B02, J06.9, J10
When CSF: 09.01.05.02
Manufacturer: NEARMEDIC PLUS LLC (Russia)

Pharmaceutical form, composition and packaging

◊ Pills round, lenticular, cream, with splashes.

Excipients: potato starch, calcium stearate, ludipress (direct compression lactose to the composition: lactose monohydrate, povidone (Kollidon 30), krospovydon (collidon CL)).

10 PC. – packings Valium planimetric (1) – packs cardboard.

Pharmacological action

The antiviral and immunomodulatory drugs. Inducer of interferon synthesis. The active substance is a sodium salt of a copolymer of (1→4)-6-0-carboxymethyl-β-D-glyukozы,(1→4)-β-D-glucose and (21→24)-2,3,14,15,21,24, 29,32-oktagidroksi-23-(karʙoksimetoksimetil)-7,10-dimethyl-4, 13-di(2-propyl)-19,22,26,30,31-pentaoksageptaciklo [23.3.2.2^16.20.0^5.28.0^8.27.0^9.18.0^12.17] dotriakonta 1,3,5(28),6,8(27), 9(18),10, 12(17), 13,15-dean.

It causes the body's so-called late-interferon, which is a mixture of alpha- and beta-interferons, with a high antiviral activity. Kagocel^® It causes interferon production in almost all cell populations, participating in the antiviral response of the organism: T- and in- lymphocytes, makrofagax, granulocytes, fibroblasts, Endothelial cells. The ingestion of one dose Kagocel^® interferon titer in blood serum reaches a maximum after 48 no. Interferon response of the body to the introduction Kagocel^® characterized by prolonged (to 4-5 d) circulating in the bloodstream of interferon. Dynamics of accumulation of interferon in the gut while taking the drug inside is not the same as the dynamics of circulating interferon titers. Serum interferon content reaches high values ​​only in 48 h after administration Kagocel^®, while in the intestine Maximum interferon production observed after 4 no.

Kagocel^® when administered at therapeutic doses nontoxic, It does not accumulate in the body. The drug is not mutagenic and teratogenic, not carcinogenic and does not have embryotoxic action.

Pharmacokinetics

Absorption and distribution

When administered into the bloodstream gets about 20% administered dose. After ingestion by 24 h accumulates mainly in the liver, less – lung, Thymus, spleen, kidney, lymph nodes. Low concentrations observed in adipose tissue, heart, muscle, testes, brain, plasma. Low content in the brain due to the high molecular weight of the drug, makes it difficult to penetrate the BBB. The plasma drug is predominantly bound form: lipids – 47%, protein – 37%. Unrelated of the drug is about 16%. With repeated daily administration V_d It fluctuates within wide limits in all organs examined, especially pronounced accumulation of the drug in the spleen and lymph nodes.

Deduction

Displayed, primarily, through the intestine: through 7 days after administration of the body is derived 88% of the administered dose, including 90% – with feces and 10% – urine. The exhaled air drug not detected.

Testimony

- Prevention and treatment of influenza and other acute respiratory viral infections in adults;

- Treatment of influenza and other acute respiratory viral infections in children 6 and older;

- Treatment of herpes in adults.

Dosage regimen

Adults

To treatment of influenza and SARS appointed in the first 2 day – by 2 tab. 3 times / day, subsequent 2 day – by 1 tab. 3 times / day. Total duration of the course 4 day – 18 tab.

Prevention of SARS wire 7-day cycle: 2 day – by 2 tab. 1 time / day, During a break in 5 days. Then the cycle is repeated. The duration of the course varies from preventive 1 weeks to a few months.

To herpes treatment appoint 2 tab. 3 times / day for 5 days. Total duration of the course 5 days – 30 tab.

Children from 6 and older

To treatment of influenza and SARS appointed in the first 2 day – by 1 tab. 3 time / day, subsequent 2 day – by 1 tab. 2 times / day. Total duration of the course 4 day – 10 tab.

Side effect

Maybe: allergic reactions.

Contraindications

- Pregnancy;

- Children up to age 6 years;

- Individual hypersensitivity.

Pregnancy and lactation

The drug is contraindicated during pregnancy.

Kagocel^® when administered at therapeutic doses nontoxic, It does not accumulate in the body. The drug is not mutagenic and teratogenic, not carcinogenic and does not have embryotoxic action.

Cautions

Most effective in the treatment Kagocel^® achieved with his appointment no later than the 4th day from the beginning of acute infection. The prophylactic drug can be used in any time, incl. and immediately after contact with an infectious agent.

Kagocel^® well with other antiviral drugs, immunomodulators and antibiotics.

Overdose

Treatment: Accidental overdose encouraged to designate excessive drinking, induce vomiting.

Drug Interactions

In an application Kagocel^® with other antiviral drugs, immunomodulators and antibiotics described additive effect.

Conditions of supply of pharmacies

The drug is resolved to application as an agent Valium holidays.

Conditions and terms

The drug should be stored in a dry, protected from light, inaccessible to children at temperature not exceeding 25 ° C. Shelf life – 2 year.